A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)Erica Brivio, C. Michel Zwaan, Franco Locatelli et al.|Blood|2020Cited by 93
Repurposing anthelmintic agents to eradicate resistant leukemiaCaterina Mezzatesta, Beat Bornhäuser, Júlia Aguadé-Gorgorió et al.|Blood Cancer Journal|2020Cited by 8
A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 StudyErica Brivio, C. Michel Zwaan, Marta López‐Yurda et al.|Blood|2019Cited by 8
Update on long-term outcomes of a cohort of patients with TCF3::HLF positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantationAida Zečkanović, Jean‐Pierre Bourquin, Brice Mouttet et al.|Haematologica|2025Cited by 3
Update on long-term outcomes of a cohort of patients with -positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantationAida Zečkanović, Jean-Pierre Bourquin, Brice Mouttet et al.|Open MIND|2025Cited by 0